Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.

Yenilmez E., Tamam L., Karaytug O., TULİ A.

Combinatorial chemistry & high throughput screening, vol.21, no.5, pp.374-380, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 5
  • Publication Date: 2018
  • Doi Number: 10.2174/1386207321666180619164726
  • Journal Name: Combinatorial chemistry & high throughput screening
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.374-380
  • Keywords: CYP450 polymorphism, pharmacogenetic, HRMA, schizophrenia, bipolar disease, drug dosage adjustment, DRUG-METABOLIZING-ENZYMES, GENETIC-POLYMORPHISM, CLINICAL-IMPLICATIONS, GENOTYPE FREQUENCIES, AFRICAN POPULATION, CYTOCHROME P4502C9, PHARMACOGENETICS, DIVERSITY, THERAPY, IDENTIFICATION
  • Çukurova University Affiliated: Yes

Abstract

Background: The interindividual genetic variations in drug metabolizing enzymes effects the impact and toxicity in plenty of drugs.